Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
P23284
UPID:
PPIB_HUMAN
Alternative names:
CYP-S1; Cyclophilin B; Rotamase B; S-cyclophilin
Alternative UPACC:
P23284; A8K534; Q6IBH5; Q9BVK5
Background:
Peptidyl-prolyl cis-trans isomerase B, known by alternative names such as CYP-S1, Cyclophilin B, Rotamase B, and S-cyclophilin, plays a crucial role in protein folding. It catalyzes the cis-trans isomerization of proline imidic peptide bonds in oligopeptides, a process essential for proper protein conformation and function.
Therapeutic significance:
The protein is implicated in Osteogenesis imperfecta 9, a severe connective tissue disorder characterized by bone fragility and susceptibility to fractures. Understanding the role of Peptidyl-prolyl cis-trans isomerase B could open doors to potential therapeutic strategies for this condition.